Charles River Labs CEVP Parisotto sells $599,710 in shares
Shannon M. Parisotto, Corporate Executive Vice President at Charles River Laboratories International, Inc. (NASDAQ:CRL), sold 2,039 shares for $599,710 at a price of $294.12 per share. This transaction was part of a pre-arranged trading plan, occurring as CRL stock trades near its 52-week high after an 82% return over the past year. The sale followed Parisotto's acquisition of the same number of shares through stock option exercise.
Edmond DE Rothschild Holding S.A. Purchases New Position in IQVIA Holdings Inc. $IQV
Edmond DE Rothschild Holding S.A. has acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV), purchasing 411,578 shares valued at approximately $79.525 million, making it their 22nd largest position. Other institutional investors have also adjusted their holdings, while company insiders have sold shares. Analysts have set new price targets, with the stock currently holding a "Moderate Buy" consensus rating.
Thermo Fisher Scientific (TMO) Climbed, So What Is Behind The Fresh Attention?
Thermo Fisher Scientific (TMO) has seen increased attention after exceeding analyst expectations with its latest quarterly revenue and earnings, and completing a Parkinson's proteomics project. This strong performance has led to a 16.6% share price return over the past 30 days and a 24.5% total shareholder return over the past year. While some valuations suggest the stock is slightly overvalued, a Discounted Cash Flow model by Simply Wall St indicates it might be modestly undervalued, prompting investors to consider both the optimistic outlook and potential risks.
Deutsche Bank AG Buys Shares of 740,473 IQVIA Holdings Inc. $IQV
Deutsche Bank AG has acquired 740,473 shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, valued at approximately $143.07 million, representing a 0.45% stake in the company. Other institutional investors have also shown interest in IQVIA, while some insiders have sold shares. Analysts have a "Moderate Buy" rating on IQV with a consensus target price of $241.88.
BlackRock Inc. Takes Position in IQVIA Holdings Inc. $IQV
BlackRock Inc. has acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, purchasing over 14.5 million shares valued at approximately $2.81 billion, representing about 8.84% of the company. Other institutional investors also adjusted their stakes in IQVIA, which recently reported strong earnings, beating analyst estimates, and announced a $2.00 billion stock repurchase program. Analysts maintain a generally positive outlook on IQV, with several firms reiterating "buy" or "overweight" ratings and increasing price targets.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
IQVIA Holdings Inc. (IQV) stock rose 3.85% to $249.28 on Wednesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average. The company's stock closed just 0.83% below its 52-week high.
227,555 Shares in IQVIA Holdings Inc. $IQV Bought by Danica Pension Livsforsikringsaktieselskab
Danica Pension Livsforsikringsaktieselskab has acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV), purchasing 227,555 shares valued at approximately $43.97 million during the second quarter. This acquisition makes Danica Pension Livsforsikringsaktieselskab own about 0.14% of IQVIA's stock. The article also details recent insider stock sales, IQVIA's financial performance, analyst ratings, and a recently authorized stock buyback plan.
Bruni J V & Co. Co. Purchases New Shares in IQVIA Holdings Inc. $IQV
Bruni J V & Co. Co. recently acquired 66,918 shares of IQVIA Holdings Inc. valued at approximately $12.93 billion, making it their 26th largest position. IQVIA, a medical research company, reported strong Q2 earnings, exceeding analyst estimates with $3.15 EPS and $4.37 billion in revenue, and authorized a $2 billion share repurchase program. Analysts maintain a "Moderate Buy" rating with an average price target of $241.88 for the stock.
Act Two Investors LLC Invests $30.67 Million in IQVIA Holdings Inc. $IQV
Act Two Investors LLC has acquired a new position in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, purchasing 158,746 shares valued at approximately $30.67 million, making it their fifth largest holding. Other institutional investors like BlackRock Inc. and Boston Partners also significantly increased their stakes in IQVIA. Despite recent insider selling, the company's stock has performed well, with positive earnings and revenue growth, and analysts maintaining a "Moderate Buy" consensus rating with an average price target of $241.88.
How Investors May Respond To Thermo Fisher Scientific (TMO) Expanding Access To Parkinson’s Proteomic Data
Thermo Fisher Scientific (TMO) has completed large-scale Olink Explore HT proteomic analysis on Parkinson's samples from The Michael J. Fox Foundation, making the data accessible for research. This initiative reinforces Thermo Fisher's role in precision medicine and its focus on innovation and recurring revenue. Investors should consider how this strengthens the company's long-term strategy, even as concerns about China exposure and margin pressure in Analytical Instruments persist.
Pallas Capital Advisors LLC Acquires New Shares in IQVIA Holdings Inc. $IQV
Pallas Capital Advisors LLC has acquired a new stake of 8,032 shares, valued at approximately $1,552,000, in IQVIA Holdings Inc. during the second quarter. Other institutional investors have also recently adjusted their holdings in the medical research company. IQVIA's stock performance shows a market cap of $39.68 billion, and the company recently announced a $2.00 billion stock buyback program, indicating the board believes its stock is undervalued.
IQVIA Holdings Company Profile & Introduction
This document provides a company profile and introduction for IQVIA Holdings. It is likely an overview of their operations, market position, and key business areas.
Plato Investment Management Ltd Invests $1.34 Million in IQVIA Holdings Inc. $IQV
Plato Investment Management Ltd recently acquired a new stake of 6,960 shares in IQVIA Holdings Inc. (NYSE:IQV) valued at approximately $1.34 million. This comes as several other hedge funds have also invested in IQVIA, with institutional investors and hedge funds collectively owning 89.62% of the stock. The medical research company recently reported strong quarterly earnings, topping analyst estimates, and has authorized a $2.00 billion stock buyback program.
Global Retirement Partners LLC Purchases Shares of 7,179 IQVIA Holdings Inc. $IQV
Global Retirement Partners LLC has acquired 7,179 shares of IQVIA Holdings Inc. (NYSE:IQV) valued at approximately $1.39 million during the second quarter. This purchase contributes to institutional investors owning nearly 90% of the company, which recently exceeded earnings and revenue expectations. Despite some insider selling, analysts maintain a "Moderate Buy" rating for IQVIA with a consensus price target of $241.88.
What set IQVIA apart after it scored 96.8 out of 100 among 50 providers?
IQVIA has been ranked as the No. 1 Pharmaceutical Technology Provider by Everest Group, achieving the highest overall score of 96.8 out of 100 among 50 evaluated providers. The company distinguished itself by offering comprehensive technology coverage across all six pharmaceutical value-chain areas, including drug discovery, clinical development, manufacturing, sales and marketing, supply chain, and pharmacovigilance. This broad coverage, combined with its proprietary data, life sciences expertise, and advanced technology, enables IQVIA to provide integrated solutions for complex, highly regulated environments.
IQVIA Holdings stock steadies above $230 as Q2 2026 growth and guidance support outlook
IQVIA Holdings' stock is trading in the mid-$230s, bolstered by solid Q2 2026 revenue growth of 8.7% to $4.37 billion, surpassing analyst expectations. The company also issued full-year guidance slightly above consensus, indicating confidence in its future performance. Despite recent short-term fluctuations, the stock maintains a positive year-to-date performance and a market capitalization of $38.95 billion, supported by a "Moderate Buy" consensus analyst rating.
10,831 Shares in IQVIA Holdings Inc. $IQV Purchased by OneDigital Investment Advisors LLC
OneDigital Investment Advisors LLC recently acquired 10,831 shares of IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, valued at approximately $2.093 million. This purchase is part of a broader trend of institutional investors buying and selling IQV shares. Analysts currently rate IQVIA as a "Moderate Buy" with an average price target of $241.88, while company insiders have recently sold a significant number of shares.
Nippon Life Global Investors Americas Inc. Purchases Shares of 4,300 IQVIA Holdings Inc. $IQV
Nippon Life Global Investors Americas Inc. recently acquired 4,300 shares of IQVIA Holdings Inc. (NYSE:IQV), valued at approximately $831,000, as institutional investors collectively own 89.62% of the company. IQVIA exceeded quarterly earnings expectations, reporting adjusted EPS of $3.15 and revenue of $4.37 billion, and has authorized a $2 billion share buyback program. Despite positive analyst ratings with a "Moderate Buy" consensus, company insiders have sold over 12,900 shares worth about $3.1 million in the last 90 days.
Focus Partners Advisor Solutions LLC Acquires New Shares in IQVIA Holdings Inc. $IQV
Focus Partners Advisor Solutions LLC has acquired 5,053 shares of IQVIA Holdings Inc. ($IQV) valued at approximately $976,000 during the second quarter. This move comes as institutional investors collectively own 89.62% of the company, and IQVIA has reported strong financial performance, exceeding quarterly expectations and authorizing a $2 billion share-repurchase program. Despite some insider selling, analyst sentiment remains positive with a "Moderate Buy" rating.
SFE Investment Counsel Invests $11.41 Million in IQVIA Holdings Inc. $IQV
SFE Investment Counsel recently acquired 59,043 shares of IQVIA Holdings Inc. (NYSE:IQV) valued at approximately $11.41 million, making it their 22nd largest holding. IQVIA reported strong quarterly earnings of $3.15 per share and $4.37 billion in revenue, surpassing analyst expectations, and authorized a $2 billion share-repurchase program. Analysts generally maintain a "Moderate Buy" rating with a target price of $241.88, despite some recent insider selling activity.
IQVIA Holdings (IQV) Reported Record Bookings And Raised Guidance, Is It Now Overvalued?
IQVIA Holdings (IQV) recently announced record net new bookings and raised its revenue and earnings guidance for 2026, leading to significant short-term stock price appreciation. Despite this strong performance, a popular narrative suggests the company is currently 4.1% overvalued, with a fair value of $232 compared to its last close of $241.52. While its P/E ratio is below peer and global averages, it trades above its own fair ratio, indicating mixed sentiment regarding its current valuation.
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors
IQVIA Holdings Inc. (IQV) stock fell 2.01% on Friday, closing at $236.66. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing slight declines. This marks the third consecutive day of losses for IQVIA Holdings Inc.
IQVIA Holdings stock trades around $242 as investors weigh recent earnings trend
IQVIA Holdings stock is currently trading around $242, maintaining a market capitalization close to $40 billion, despite recent quarterly earnings showing a softer trend. Investors are focusing on the company's valuation, which includes a P/E multiple in the low 30s, and its future growth prospects in the health data and clinical research sector. Upcoming earnings reports will be critical in determining whether the stock's current valuation is justified given the slower earnings momentum.
Cingulate’s ADHD Drug Patent Protects Its Formulation Through 2042
Cingulate Inc. reported its second-quarter 2026 financial results, highlighting $28.4 million in cash and cash equivalents, expected to fund operations into mid-2027. The company is advancing its CTx-1301 ADHD drug toward NDA resubmission following an FDA Complete Response Letter and secured a new U.S. patent extending protection for CTx-1301's formulation until December 2042. Commercialization efforts are underway, including distribution agreements and market access strategies, despite an increased net loss driven by higher SG&A expenses.
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Biomea Fusion Inc (BMEA), detailing analyst ratings and price targets. Seven analysts have given BMEA a "Buy" rating with a target price of $6.50, representing a significant upside. The report also includes past and projected EPS figures and a peer comparison.
Amgen Stock And The Price Of A Promise
Amgen recently raised its full-year revenue guidance, typically a positive signal, but its stock has not seen a significant celebratory pop. While the company's current performance is strong with multiple products showing double-digit growth, the market appears to have already factored this in. Investors are now looking for the next major catalyst, particularly from Amgen's drug pipeline, especially its experimental weight-loss treatment MariTide, to justify further stock appreciation.
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
IQVIA (IQV) stock has gained 41.5% in the last three months, outperforming its industry and the S&P 500. This growth is attributed to record net bookings, a solid backlog in its R&D solutions, and an uplifted 2026 financial outlook. The company's shareholder-friendly actions, including significant share repurchases, also contribute to investor confidence.
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Acrivon Therapeutics Inc (ACRV), including analyst ratings, price targets, and expected EPS and revenue figures. Based on ratings from 8 analysts, the stock has a "Buy" trend with a target price of USD 11.50, representing a potential upside of 568.60%. The company's expected revenue for the next quarter is $165.71K, and the EPS is projected at -$0.47.
IQVIA Holdings Inc (IQV) GF Score of 94/100: A Signal of Strong Outperformance Potential
IQVIA Holdings Inc (IQV) has achieved a GF Score of 94/100, indicating strong outperformance potential, according to GuruFocus. The company demonstrates exceptional strength in profitability, growth, valuation, and momentum, with shares currently at $242.82 and a three-month gain of 39.91%. While its financial strength ranks lower due to debt from acquisitions, its robust operational performance and strategic positioning in the life sciences industry make it an attractive prospect for investors.
NewEdge Advisors LLC Increases Stock Holdings in IQVIA Holdings Inc. $IQV
NewEdge Advisors LLC increased its stake in IQVIA Holdings Inc. by 21.5% in the first quarter, now holding shares valued at approximately $6.03 million. This increase comes as IQVIA reported strong quarterly earnings, surpassing analyst expectations with adjusted EPS of $3.15 and revenue of $4.37 billion, and authorized a $2 billion share buyback program. Despite some insider selling, analyst sentiment remains positive, with a "Moderate Buy" consensus rating and several firms raising price targets for the medical research company.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
IQVIA Holdings Inc. (IQV) saw its stock rise by 1.38% to $241.99 on Monday, outperforming the broader market. This gain occurred on a day when both the S&P 500 Index and the Dow Jones Industrial Average experienced slight declines. It marked the second consecutive day of gains for IQVIA Holdings Inc.
DDM Dividend: 1.18% Yield, $0.61/Share — History & Dates
This article provides a detailed history of dividends for ProShares Ultra Dow30 2x Shares (DDM), including its current dividend yield of 1.18% ($0.61 per share annually) and a payout ratio of 0.34. DDM has been consistently paying dividends since 2006, demonstrating a 5-year dividend growth rate of 10.03%. The article also includes a complete historical table of its 72 dividend payments.
Legacy Wealth Management LLC MS Sells 8,935 Shares of IQVIA Holdings Inc. $IQV
Legacy Wealth Management LLC MS reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 53.5% in the second quarter, selling 8,935 shares and retaining 7,752 shares valued at approximately $1.5 million. Despite this, IQVIA reported strong Q2 earnings, beating analyst estimates with $3.15 EPS and $4.37 billion in revenue, and authorized a $2 billion share-repurchase program. Analysts maintain a "Moderate Buy" rating for IQV, though company insiders have recently sold shares worth about $3.1 million.
Adlai Nortye Ltd (ANL) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Adlai Nortye Ltd (ANL), highlighting that analysts predict a "Buy" trend based on the ratings of 6 analysts. The target price for ANL is forecasted at USD 28.600, representing a significant upside potential. However, it notes that relevant financial data for detailed forecasting has not yet been disclosed by the company.
How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors
IQVIA Inc. (IQV) recently announced a collaboration with Medera Inc. to advance cardiac gene therapies and human-based drug discovery, alongside raising its full-year 2026 revenue guidance to US$17.28–US$17.48 billion. This alliance integrates IQVIA's trial execution and commercialization infrastructure with Medera's gene therapy programs, reinforcing IQVIA's role in advanced cardiovascular research. While the Medera deal and increased revenue outlook support IQVIA's investment narrative, investors are advised to consider ongoing pricing pressures and margin strain in CRO contracts.
Should Medpace’s (MEDP) Golden Cross and Upgraded Estimates Prompt a Fresh Look at Its Valuation?
Medpace Holdings (MEDP) recently experienced a "golden cross" and received upgraded earnings estimates, suggesting positive technical momentum and improved financial prospects. While these developments highlight stronger near-term performance and reinforce the company's backlog conversion, investors should consider the risk of concentrated client exposure and the sustainability of current growth and margin levels. Despite these positive indicators, Medpace's projected fair value suggests a potential downside to its current price.
Labcorp Holdings Inc. (LH) stock price, news, quote and history
This article provides a detailed financial overview of Labcorp Holdings Inc. (LH), including its current stock price, recent news like a dividend announcement, and comprehensive financial data. It covers key metrics such as market capitalization, P/E ratio, earnings, revenue, analyst ratings, and historical performance compared to the S&P 500. The company's business segments, services, and strategic collaborations are also highlighted.
Community Trust & Investment Co. Increases Position in IQVIA Holdings Inc. $IQV
Community Trust & Investment Co. has increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 5% in the second quarter, bringing its total holdings to 92,668 shares valued at $17.9 million. This comes as IQVIA exceeded quarterly earnings expectations with adjusted EPS of $3.15 and revenue of $4.37 billion, and also authorized a $2 billion share repurchase program. Despite insider sales totaling $3.1 million, analysts maintain a "Moderate Buy" rating with a consensus price target of $241.88.
Assenagon Asset Management S.A. Purchases 109,284 Shares of IQVIA Holdings Inc. $IQV
Assenagon Asset Management S.A. significantly increased its stake in IQVIA Holdings Inc. by 47.3% in the second quarter, acquiring an additional 109,284 shares. This move is part of a broader trend of institutional investors modifying their holdings in IQVIA, which includes other major purchases by Boston Partners, Norges Bank, and Victory Capital Management Inc. The medical research company recently posted strong earnings, exceeding analyst expectations, and its board approved a $2.00 billion share repurchase plan.
Should ICON’s Anthropic AI Collaboration Amid Weaker Q2 Profitability Require Action From ICON (ICLR) Investors?
ICON plc reported weaker Q2 2026 net income despite slightly higher sales, reaffirming full-year revenue guidance. The company also announced a multi-year collaboration with Anthropic to integrate Claude's AI into its clinical trial workflows, aiming to enhance protocol optimization, site selection, and real-time study monitoring. While the AI partnership could influence ICON's long-term competitive edge, investors are advised to monitor the near-term earnings risks associated with cancellations and trial volatility.
IQVIA Holdings Inc (IQV) Stock News Today
This article provides recent news updates for IQVIA Holdings Inc (IQV) stock, including its latest closing price, market capitalization, and P/E ratio. It highlights two recent news items: a report on Amgen Inc (AMGN) stock movement from July 28, and IQVIA Holdings Inc's own stock closing up by 9.60% on May 5. The page serves as a news and analysis hub for IQV investors.
Balefire LLC Sells 12,141 Shares of IQVIA Holdings Inc. $IQV
Balefire LLC significantly reduced its stake in IQVIA Holdings Inc. by selling 12,141 shares, retaining 4,326 shares valued at $836,000. Despite this, institutional investors collectively own 89.62% of IQVIA, and the company reported strong quarterly earnings, exceeding analyst estimates, and authorized a $2 billion share repurchase program. Analysts maintain a "Moderate Buy" rating with a target price of $241.88, although insiders have recently sold shares worth about $3.1 million.
IQVIA Holdings (IQV) Expands Medera Partnership, Is The Stock Fully Valued?
IQVIA Holdings (IQV) recently expanded its partnership with Medera, alongside raising 2026 revenue guidance and engaging in share repurchases. Despite a significant 90-day stock price return, valuation models present conflicting views on its current price; a common narrative suggests it's 20% overvalued at $232.00, while a DCF model indicates it's 36% undervalued. The company faces ongoing pressures from CRO pricing and high leverage.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
IQVIA Holdings Inc. (IQV) shares rose 2.70% to $238.70, outperforming the S&P 500 Index and the Dow Jones Industrial Average on a strong trading day. The company's stock closed 5.04% below its 52-week high of $251.36. This performance occurred amidst a generally favorable market session.
IQVIA Holdings Inc (IQV) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IQVIA Holdings Inc (IQV), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes that the stock is currently suitable for range-bound swing trading, trading between resistance at $256.66 and support at $202.90. The analysis includes a breakdown of various technical indicators and moving averages, concluding with a neutral signal based on these metrics.
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors
Shares of IQVIA Holdings Inc. (IQV) fell by 1.53% on Thursday, closing at $232.43. This performance was weaker than the overall market, as the S&P 500 Index declined by 0.18% and the Dow Jones Industrial Average dropped by 0.85%. The stock is now 7.53% below its 52-week high of $251.36 reached on July 29th.
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace Holdings, Inc. (MEDP) exhibits compelling growth with double-digit earnings, strong profitability, and improving bookings, along with a significant pipeline for 2027. However, its valuation is considerably higher than industry and market averages. While the company's operational quality is high, the premium valuation and potential for uneven booking visibility suggest a selective approach rather than aggressive buying.
IQVIA (IQV) Teams Up With Medera To Push Cardiac Gene Therapy Forward
IQVIA Holdings (NYSE:IQV) has announced a new alliance with Medera Inc. to advance cardiac gene therapy and human-based drug discovery by leveraging IQVIA's clinical trial infrastructure and Medera's gene therapy work. This partnership expands IQVIA's presence in gene therapies and innovative drug development, aligning with its existing focus on AI-powered data platforms and R&D solutions. Investors should monitor the collaboration's progress for signs of commercial traction and its impact on IQVIA's resource allocation and financial metrics.
IQVIA (IQV) Teams Up With Medera To Push Cardiac Gene Therapy Forward
IQVIA Holdings (IQV) has announced a new partnership with Medera Inc. to advance cardiac gene therapy and human-based drug discovery. This collaboration aims to leverage IQVIA's global clinical trial and commercialization capabilities with Medera's gene therapy work, focusing on programs that use human-based predictive models. For investors, this alliance positions IQVIA more deeply in complex, specialized areas of life sciences, potentially influencing resource allocation towards AI tools and clinical operations in gene therapies.
MGX|Metagenomi Inc|Price:1.215|Chg%:+0.005
Metagenomi Inc (MGX) has a TradingKey Stock Score indicating stable fundamentals and significant growth potential, although its valuation is considered fairly valued within the Biotechnology & Medical Research industry. The company, focused on precision genetic medicine, has seen high institutional ownership and multiple "Buy" ratings from analysts, despite a projected short-term downtrend in stock price. Key strengths include high profit growth and its growing phase, while risks involve being overvalued and recent institutional selling.
